Compare Medpace Holdings Inc (MEDP) vs Oxford Lane Capital Corp (OXLC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Medpace Holdings Inc vs Oxford Lane Capital Corp — how do they compare? Medpace Holdings Inc trades at $611.57 (market cap $16.82B), while Oxford Lane Capital Corp trades at $8.58 (market cap $835.71M). The key difference: Medpace Holdings Inc is far larger — about 20.1× Oxford Lane Capital Corp's market cap, and Oxford Lane Capital Corp pays a 28.15% dividend while Medpace Holdings Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Medpace Holdings Inc for 14 Days and Oxford Lane Capital Corp for 50 Days on average.
| MEDP | OXLC | |
|---|---|---|
Market Cap | $16.82B | $835.71M |
Volume | 223,093 | 1,125,263 |
Sector | Health | Financials |
52-Week High | $630.19 | $16.74 |
52-Week Low | $393.42 | $8.15 |
Typical Hold Time | 14 Days | 50 Days |
Enterprise Value | $16.44B | $1.23B |
Dividend Yield | — | 28.15% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Medpace (MEDP) trades at $617.47, up 2.19% with strong quarterly earnings beats and robust profitability metrics. The stock shows neutral technical signals with key resistance at $620, while fundamentals reveal impressive ROE of 162.15% and consistent revenue growth to $2.8B projected for 2026. Recent CEO stock sales and mixed institutional activity create balanced sentiment ahead of Q3 earnings announcement on October 21, 2026.
MEDP presents growth potential with analyst consensus target of $620.44 and strong historical execution, though elevated valuations (P/E 35.41) and insider selling warrant caution. The stock's upside depends on continued earnings delivery amid competitive medical services landscape.
OXLC trades at $8.655, up 2.3% today, but remains in a bearish technical trend with significant earnings volatility. The company reported a net loss of $585 million in 2026, missing EPS estimates for three consecutive quarters, while maintaining a high dividend payout. Analyst sentiment is mixed with a 50% buy rating, but technical indicators show strong selling pressure.
The outlook is cautious due to deteriorating fundamentals and high payout risks, though the stock trades below book value. Key risks include unsustainable dividends and NAV erosion, while potential upside hinges on CLO market recovery and cost management improvements.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Medpace Holdings Inc
Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →About Oxford Lane Capital Corp
Oxford Lane Capital Corp. is a non-diversified, closed-end management investment company. Its primary investment objective is to achieve high current income, with a secondary objective of capital appreciation. The company primarily invests in equity and junior debt tranches of collateralized loan obligations (CLOs), which are pools of corporate loans. OXLC is known for its high-yield distribution policy and provides investors with leveraged exposure to the CLO market.
Read more on OXLC →
